Fabry Disease Treatment Market Report 2026

The fabry disease treatment market size has grown strongly in recent years. It will grow from $2.27 billion in 2025 to $2.48 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to improved awareness of rare genetic disorders, approval of enzyme replacement therapies, expansion of genetic testing, growth in specialty hospitals, increased patient advocacy.

The fabry disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in gene therapy, growing use of personalized medicine, improved newborn screening programs, expansion of oral therapies, increased rare disease funding. Major trends in the forecast period include increasing adoption of enzyme replacement therapy, growing focus on early genetic diagnosis, expansion of oral chaperone therapies, rising research in gene therapy approaches, improved patient access to rare disease treatments.

The rising prevalence of renal diseases is expected to drive growth in the Fabry disease treatment market in the coming years. Renal diseases, also referred to as kidney diseases, encompass any condition that impairs kidney function. The incidence of renal diseases is increasing due to genetic factors, lifestyle habits, environmental influences, and underlying health conditions. Fabry disease results from the buildup of globotriaosylceramide (Gb3) in kidney cells, causing damage and dysfunction, which underscores the importance of early detection and intervention to prevent kidney complications. For example, in March 2023, the International Society of Nephrology (ISN), a Belgium-based professional society, reported that around 850 million people globally were living with chronic kidney disease (CKD), reflecting a rise compared to previous years. Consequently, the growing prevalence of renal diseases is fueling the expansion of the Fabry disease treatment market.

Key players in the Fabry disease treatment market are focusing on developing plant cell-based therapies to improve therapeutic effectiveness, reduce treatment costs, and enhance patient outcomes through innovative and sustainable approaches. Plant cell-based treatment for Fabry disease involves utilizing plant cells to produce enzymes that patients with Fabry disease lack. These plant-derived enzymes serve as therapeutic options to replace missing or defective enzymes in the body, helping alleviate symptoms and improve patient health. For instance, in May 2023, Chiesi Global Rare Diseases, an Italy-based pharmaceutical company, and Protalix BioTherapeutics Inc., an Israel-based pharmaceutical company, received approval for ELFABRIO. ELFABRIO offers an alternative treatment option for Fabry disease patients. It is an enzyme replacement therapy (ERT) in which the recombinant human α-Galactosidase-A enzyme is produced in plant-cell culture and PEGylated to significantly extend its half-life. This therapy reduces dosing frequency, enhances convenience, and improves overall management of Fabry disease symptoms, ultimately enhancing patient quality of life.

In March 2024, CENTOGENE, a Germany-based biotechnology research firm, extended its partnership with Takeda Pharmaceutical Company Limited. This collaboration ensures Takeda's continued access to diagnostic testing for patients worldwide. The agreement improves patient access to fast and reliable diagnostics for lysosomal storage disorders (LSDs), including Fabry disease, Gaucher disease, and Hunter syndrome. Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, focuses on developing therapies for lysosomal storage disorders such as Fabry disease.

Major companies operating in the fabry disease treatment market are Sanofi S.A., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Protalix BioTherapeutics, Avrobio Inc., Freeline Therapeutics Holdings PLC, M6P Therapeutics Inc., Yuhan Corporation, Orchard Therapeutics Ltd., Regenxbio Inc., Synlogic Inc., AceLink Therapeutics Inc., Greenovation Biotech GmbH, CANbridge Life Sciences Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Daiichi Sankyo Company Ltd., Audentes Therapeutics Inc., Genesis Therapeutics Inc., Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co Ltd., ISU Abxis Co Ltd.

North America was the largest region in the fabry disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fabry disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the fabry disease treatment market by increasing costs of imported biologics, enzyme therapies, and diagnostic reagents. Specialty hospitals in North America and Europe are most affected due to reliance on imported treatments. These tariffs raise therapy costs by increasing expenses for lifelong enzyme replacement and diagnostics. However, they encourage regional biopharmaceutical manufacturing, supporting localized production of rare disease therapies.

The fabry disease treatment market research report is one of a series of new reports that provides fabry disease treatment market statistics, including fabry disease treatment industry global market size, regional shares, competitors with a fabry disease treatment market share, detailed fabry disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fabry disease treatment industry. This fabry disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fabry disease is a rare genetic condition caused by a deficiency of the enzyme alpha-galactosidase A. This enzyme shortage results in the accumulation of a type of fat called globotriaosylceramide (Gb3 or GL-3) within the body's cells, leading to a variety of symptoms and complications such as pain, kidney failure, heart disease, and stroke. The main goal of treating Fabry disease is to reduce Gb3 buildup, relieve symptoms, prevent or slow organ damage, and enhance the overall quality of life for patients.

The key types of treatments in the Fabry disease treatment market include substrate reduction therapy, enzyme replacement therapy, chaperone therapy, and others. Substrate reduction therapy (SRT) works by decreasing the accumulation of specific substances in the body. These therapies can be administered orally or intravenously. Fabry disease can present in different severities, including classic Fabry disease and late-onset Fabry disease. Treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The fabry disease treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, enzyme replacement therapy, gene therapy, disease management programs, and patient education and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The Fabry disease treatment market also includes sales of Agalsidase alfa, Agalsidase beta, and Migalastat. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.